Liquidity & Technical

Liquidity & Technical

A small-cap turnaround tape has done its work in the last twelve months: SCHL has roundtripped from $17 back to $42 on a market that can absorb meaningful but not unlimited size — a 5% position within five trading days needs total AUM under roughly $240M. Price action is constructive (uptrend intact, MACD positive, RSI off overbought) but the rally has come on fading volume into resistance at the 52-week high. Setup is constructive on a 3-to-6 month view with clearly defined invalidation; capacity, not signal, is the binding constraint.

Portfolio implementation verdict

Price snapshot

A name that traded sideways between $35 and $48 for most of the prior eight years has just delivered a +147% twelve-month total return off a deep April-2025 capitulation low at $16.54. The print sits within $0.70 of the 52-week high and 13.7% below the all-time high of $48.76 set in 2018.

Price history and the 200-day line

Price is decisively above the 200-day SMA — the close at $42.10 sits 29.3% above the 200-day at $32.57 and 5.5% above the 50-day at $39.90. This is an uptrend regime, but a very young one: the 200-day is still rising from a base that took most of 2025 to form, and the gap between price and the long-term moving average is now wider than at any point since the 2022 high.

Relative strength versus market and sector

The relative-performance dataset for this run ships without benchmark series populated — the broad-market (SPY) and sector (XLC) comparison series are empty in the underlying file. A like-for-like rebased comparison cannot be drawn from public tape data alone here. As a directional proxy, SCHL's +40.5% YTD print materially outruns a broad US tape that has traded in a low-double-digit range over the same window, so relative strength is supportive but not formally measured in this section.

Momentum: RSI and MACD

RSI sits at 60.7 — bullish but with room to run before the 70 overbought threshold, and well off the 74 print from late-March 2026. MACD histogram has flipped positive in the last week after a six-week negative stretch through April-May, with the MACD line ($0.72) now back above signal ($0.51). Near-term momentum (1-to-3 month) reads constructive without being euphoric, and that distance from the overbought line is the most actionable feature of the panel: there is still fuel before a momentum stall is visible on a standard oscillator.

Volume, sponsorship, and volatility regime

The volume signature is the soft spot in the bull case. The 50-day average volume peaked near 650k shares in late April 2026 around the post-Q3-earnings rally and has since faded to roughly 547k, while the most recent 20-day ADV of 285k is below half of that. Price has continued higher into June on materially thinner sponsorship — a classic late-stage tape divergence that does not necessarily kill the trend, but does mean any earnings disappointment or macro shock will land into thin support.

Top historical volume-spike days

Six of the eight largest volume bursts on record landed on red days, and three of the four most recent prints (December 2024, September 2025, December 2025) were earnings-related capitulation events near the cycle lows. The current rally has not yet been validated by an equivalent up-volume spike, which is the missing piece of conviction in the tape.

Realized volatility regime (5-year)

Realized 30-day vol at 36% sits between the 5-year p50 (29%) and p80 (43%) — a normal-to-elevated regime, well below the 70%+ readings of August-September 2025 when the stock was capitulating. Position sizing should still assume daily moves in the 1.5%-2.0% range; the median 60-day daily range of 0.65% understates the tail.

Institutional liquidity panel

This is a small-cap publishing name, not a mega-cap. Capacity discipline matters.

ADV and turnover

20-day ADV of $11.5M tracks roughly half of the 60-day average of $21.8M — the rally cooled volume materially after the late-April spike. Annual turnover of 353% means the entire float changes hands more than three times per year, which is supportive context for institutional accumulation but flatters the picture: a one-day spike can swing the multi-day average.

Fund-capacity table

The math reverses cleanly: a fund running 5% portfolio weights can absorb SCHL up to roughly $240M AUM at 20% participation, or roughly $120M at the more disciplined 10% participation cap. At 10% concentrated weights, those numbers compress to $120M / $60M — a number that excludes most mid-cap managers above $500M AUM, who would need at least three weeks to scale in cleanly.

Liquidation runway

A 0.5% issuer-level position ($5.8M) clears in three trading days at 20% participation; a 1% position ($11.6M) takes exactly a week; anything north of 2% becomes a multi-week unwind. The 60-day median daily range of 0.65% is well under the 2% impact-cost threshold, so order-driven slippage on routine flow is not the constraint — participation rate and adverse-selection on event days are.

Bottom line on size: the largest issuer-level position that clears the 5-day threshold is 1.0% of market cap at 20% ADV (or 0.5% at the more conservative 10% ADV cap). Anything bigger should be built or unwound over multiple weeks, ideally avoiding the four-times-a-year earnings windows where the volume-spike table shows ±10-20% gap-risk.

Technical scorecard and stance

Stance — constructive setup on a 3-to-6 month view, capacity-bound. A clean weekly close above $42.77 (the 52-week high) would confirm continuation toward the all-time high at $48.76 and mark a full round-trip of the 2024-25 derate. A break of the 50-day at $39.90 on rising volume invalidates the near-term setup and puts the 200-day at $32.57 in play as the only meaningful support; that level is where the post-capitulation base completed in late 2025. The signal is constructive but not loud: the rally has come on materially thinner volume than the selloff. An up-volume confirmation around the July Q4 print is the missing piece. Liquidity is the binding constraint for funds above roughly $240M AUM, which should treat SCHL as watchlist-only or build over two-to-three weeks rather than chase a one-week breakout.